Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.
Allergy
View this publicationAllergy
View this publicationEuropean journal of haematology
View this publicationNeurological research and practice
View this publicationNature reviews. Drug discovery
View this publicationBiomolecules
View this publicationRedox biology
View this publicationBiomedicines
View this publicationNature communications
View this publicationBMC medical genomics
View this publicationNature communications
View this publication